August 30, 2016 5:21pm
… On no news, vacation hiatuses and low to middling volume
Sets-up a pricing speed bump as a holiday weekend beckons
Pre-open indication’s tally: 3 hits (AGTC, BTX and STML) and 1 miss (BSTG)
Do you care what happened today, you should … because it has implications to Wednesday's sector activity?
I answer one question; in which company should investors put, keep and commit their money!
If you were a subscriber, you would be reading where “our” universe had gone today!
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. stocks closed lower Tuesday, as investors analyzed strong consumer data while keeping an eye on the Fed ahead of Friday's jobs report.
The NASDAQ closed DOWN -9.34 or -0.18% to 5,222.29 and the DOW closed DOWN -48.69 or -0.26% to 18,454.30.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 27/14 and 2 flats;
- The mid-day stayed positive with an A/DL of 25/15 and 3 flats;
- The closing bell was slightly positive with A/DL of 22/19 and 2 flats;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCGT&RT) sector was positive at the opening bell, stayed positive at the mid-day with the sector closing slightly positive.
- I will reiterate from this morning’s post, “What is their current dynamic? As the real question is how much risk is in the last and next trade?”
A set-up for a downdraft – especially before a long holiday weekend – who wants to be LONG!
… After 3 positive up days, I’d be grabbing my ankles …
I’m still holding on to “some” equities, recommending BUYING the oversold while sticking my head in the sand until after Labor Day!
Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right and investors make money!
Today’s Bottom Line:
The closer we get to Friday and a holiday weekend, it's likely the sector gets more volatile and depreciating
Pre-open indication’s tally: 3 hits and 1 miss:
- Applied Genetic Technologies (AGTC) closed UP +$0.04 – hit;
- Biostage (BSTG) closed UP +$0.04 – miss;
- BioTime (NYSEMKT: BTX) closed UP +$0.05 – hit;
- Stemline (STML) closed DOWN -$0.22 – hit;
Review my fear gauge or the CBOE Volatility Index (VIX):
- Tuesday traded 13.4;
- Monday traded 13.1;
- Friday traded near 13.65;
- Thursday traded near 14;
- Wednesday traded 13.39;
- Last Tuesday traded 12.19;
Decliners:
- BioLife Solutions (BLFS) -5.85%;
- ReNeuron (RENE.L ) -4.35% after Monday’s +4.55% after Friday’s -4.55%;
- Mesoblast (MESO) -3.16%;
- StemCells (STEM) -3.11% after Monday’s FLAT at $1.61;
- Stemline (STML) -2.53%
Advancers:
- Neuralstem (CUR) +11.48% after Monday’s +7.91% - be ready for a dip;
- VistaGen (VTGN) +10.37% after Monday’s -2.81% after Friday’s -7.81% after Thursday’s+1.25%;
- Capricor (CAPR) +3.35% after Monday’s -3.71%;
- Biostage (BSTG) +4.29% after Monday’s +5.16% - be ready for a dip;
- Spark therapeutics (ONCE) +2.87%
Flat:
- Organovo (ONVO) at $3.91;
- Cesca Therapeutics (KOOL) at $4.00
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
